Qiagen (NYSE:QGEN) and Dermata Therapeutics (NASDAQ:DRMA) Head to Head Survey

Dermata Therapeutics (NASDAQ:DRMA) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.

Volatility & Risk

Dermata Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.

Insider and Institutional Ownership

8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 18.5% of Dermata Therapeutics shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Dermata Therapeutics and Qiagen”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$12.29 million	($7.81)	-0.17
Qiagen	$2.09 billion	4.91	$424.88 million	$2.02	24.07

Qiagen has higher revenue and earnings than Dermata Therapeutics. Dermata Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Dermata Therapeutics and Qiagen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1	0	1	0	2.00
Qiagen	0	8	4	0	2.33

Dermata Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 640.74%. Qiagen has a consensus target price of $55.20, suggesting a potential upside of 13.53%. Given Dermata Therapeutics’ higher possible upside, equities research analysts plainly believe Dermata Therapeutics is more favorable than Qiagen.

Profitability

This table compares Dermata Therapeutics and Qiagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-191.95%	-140.15%
Qiagen	20.33%	14.56%	8.62%

Summary

Qiagen beats Dermata Therapeutics on 11 of the 13 factors compared between the two stocks.

About Dermata Therapeutics

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.